Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs topotecan in relapsed small cell lung cancer
CTR20160578Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in small cell lung cancer (SCLC), sponsored by Bristol Myers Squibb. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20160578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160578.